3 Things That Matter Most for Eli Lilly Now

Eli Lilly faces three key challenges despite its GLP-1 drug success: over-reliance on weight-loss medications (nearly two-thirds of revenue), inevitable growth slowdown as the market matures, and execution risk from acquisitions into new treatment areas. While the company's diversification strategy is prudent, investors should monitor these factors as the GLP-1 story may eventually lose momentum.